ABT · 10-Q · 2026Q3 · Full report
Research and Development Investment
ABBOTT LABORATORIES · 2026-11-04 · Importance 47 · Surprise 48 · Matches filing data
R&D expense increased $154 million, or 20.1%, to $920 million in the third quarter of 2026. For the first nine months, R&D expense rose $372 million, or 16.9%, to $2.6 billion. The increases primarily reflected the addition of Exact Sciences and continued investment in development programs across multiple businesses.
Key facts
- R&D expenses increased $154 million to $920 million, or 20.1%, in the third quarter of 2026 versus the prior year. source
- R&D expenses increased $372 million to $2.6 billion, or 16.9%, in the first nine months of 2026 versus the prior year. source
- R&D expense increases in the third quarter and first nine months of 2026 primarily reflected Exact Sciences and continued investment in development programs across multiple businesses. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -2.9% | R&D expenses increased $372 million to $2.6 billion, or 16.9%, in the first nine months of 2026 versus the prior year. |